Johnson & Johnson
Johnson & Johnson Announces Strong Q1 2024 Performance and Dividend Increase
Summary
Johnson & Johnson reported strong first-quarter 2024 results with a 2.3% increase in sales to $21.4 billion and a 12.4% increase in adjusted earnings per share (EPS) to $2.71. The company also announced a 4.2% increase in its quarterly dividend rate, marking the 62nd consecutive year of dividend increases. The Board of Directors declared a new quarterly dividend of $1.24 per share, payable on June 4, 2024, to shareholders of record as of May 21, 2024.
Profitelligence Alerts
Get alerts for JNJ
Be first to know when Johnson & Johnson files with the SEC.
Filing Categories
Exhibits (3)
Advertisement
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Official SEC Documents
Advertisement